Secret Survey Roots Out Korean Firms Offering Rebates
This article was originally published in PharmAsia News
Executive Summary
In an unprecedented move to eliminate rebates in the pharma industry, South Korean pharma firms have conducted an anonymous survey to identify firms suspected of being involved in the practice in return for prescriptions.
You may also be interested in...
Novartis Korea May Face Business Suspension In Rebate Probe
Novartis’ South Korean subsidiary could face a business suspension and other administrative measures after prosecutors indicted several employees without detention on charges of illegal rebate payments.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.